<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541082</url>
  </required_header>
  <id_info>
    <org_study_id>ONC206-01</org_study_id>
    <secondary_id>NIH 20C0069</secondary_id>
    <nct_id>NCT04541082</nct_id>
  </id_info>
  <brief_title>Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms</brief_title>
  <official_title>A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Chimerix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this phase 1 trial is to determine the maximum tolerated dose (MTD),&#xD;
      food effect, safety and tolerability of oral ONC206 in patients with recurrent, primary CNS&#xD;
      neoplasms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>28 Days</time_frame>
    <description>To determine the MTD of single agent oral ONC206</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Central Nervous System Neoplasms</condition>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma, Adult</condition>
  <condition>Anaplastic Oligodendroglioma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Pilocytic Astrocytoma</condition>
  <condition>Oligodendroglioma</condition>
  <condition>Gliomatosis Cerebri</condition>
  <condition>Pleomorphic Xanthoastrocytoma</condition>
  <condition>Anaplastic Pleomorphic Xanthoastrocytoma</condition>
  <condition>Diffuse Midline Glioma, H3 K27M-Mutant</condition>
  <condition>Ependymoma</condition>
  <condition>Ependymoma, Anaplastic</condition>
  <condition>Medulloblastoma</condition>
  <condition>Teratoid Rhabdoid Tumor</condition>
  <condition>Neuroectodermal Tumors, Primitive</condition>
  <condition>Neuroectodermal Tumors</condition>
  <condition>Anaplastic Meningioma</condition>
  <condition>Atypical Meningioma</condition>
  <condition>Choroid Plexus Neoplasms</condition>
  <condition>Pineal Tumor</condition>
  <condition>Diffuse Astrocytoma</condition>
  <condition>Glial Tumor</condition>
  <arm_group>
    <arm_group_label>ONC206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONC206</intervention_name>
    <description>ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors</description>
    <arm_group_label>ONC206</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years with a recurrent, primary CNS neoplasm. Primary CNS neoplasms included&#xD;
             in this study: glioblastoma and glioblastoma histologic subtypes, gliosarcoma, primary&#xD;
             CNS sarcomas, anaplastic glial neoplasms including anaplastic astrocytoma, anaplastic&#xD;
             oligodendroglioma, anaplastic mixed neuronal-glial tumors, and pilocytic astrocytoma&#xD;
             with anaplastic features, diffuse astrocytoma, oligodendroglioma, gliomatosis cerebri,&#xD;
             pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, diffuse&#xD;
             midline gliomas and histone mutated gliomas, ependymoma, anaplastic ependymoma, and&#xD;
             all ependymoma subtypes, medulloblastoma and all medulloblastoma subtypes, ATRT,&#xD;
             primary CNS embryonal/primitive neuroectodermal tumors, atypical and anaplastic&#xD;
             meningiomas, choroid plexus tumors, and pineal region tumors.&#xD;
&#xD;
          -  Advanced disease after having received established standard of care treatment for&#xD;
             their disease and have no standard treatment options available&#xD;
&#xD;
          -  Karnofsky Performance Score (KPS) of greater than or equal to 70.&#xD;
&#xD;
          -  Measurable or evaluable disease defined by RANO criteria. The exception will be&#xD;
             patients who have had surgery in the past 4 weeks, patients who are post-operative&#xD;
             after a maximal resection will be allowed to enroll after 4 weeks from surgical&#xD;
             resection.&#xD;
&#xD;
          -  Washout for prior investigational or approved cytotoxic chemotherapy is 28 days prior&#xD;
             to the first dose of ONC206; 42 days in the case of nitrosoureas; 28 days or 5&#xD;
             half-lives (whichever is less; but not less than 14 days) in case of investigational&#xD;
             or approved molecularly targeted agent; 14 days in the case of radiotherapy.&#xD;
&#xD;
          -  Patients will be required to enroll on the NCI Neuro-Oncology Branch natural history&#xD;
             study (16-C-0151).&#xD;
&#xD;
          -  No major surgery in the prior 4 weeks&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
          -  An available tumor specimen (paraffin-embedded block and/or frozen tissue) from prior&#xD;
             resection or biopsy, ≥15 unstained slides for IHC analysis.&#xD;
&#xD;
          -  Ability to swallow oral capsules.&#xD;
&#xD;
          -  Ability to tolerate an MRI study with intravenous gadolinium contrast.&#xD;
&#xD;
          -  Men and women must use double barrier contraceptives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior bevacizumab for treatment of high-grade glioma&#xD;
&#xD;
          -  Known HIV-positive test on combination antiretroviral therapy&#xD;
&#xD;
          -  Active cardiac disease&#xD;
&#xD;
          -  Ischemic or hemorrhagic stroke in last 3 months&#xD;
&#xD;
          -  Refractory epilepsy and patients with primary or secondarily generalized seizures in&#xD;
             the 28 days before enrollment are excluded. Peri-operative seizures occurring within 7&#xD;
             days of surgery with resolution by day 8 after surgery are allowable. Patients must be&#xD;
             on stable doses of one or two seizure medications for 14 days prior to study&#xD;
             enrollment.&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function&#xD;
&#xD;
          -  Concurrent use of warfarin sodium or other Coumadin-derivative anti-coagulants&#xD;
&#xD;
          -  Concurrent use of strong inhibitors or inducers of CYP3A4, 2D6, 1A2, 2C9 and 2C19 are&#xD;
             excluded at least 14 days prior to and throughout the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Gilbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations Oncoceutics</last_name>
    <phone>1-844-ONCORXS</phone>
    <email>info@oncoceutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Mentges, RN, CEN, MSN</last_name>
      <phone>240-760-7126</phone>
      <email>Kelly.mentges@nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Anaplastic Astrocytoma</keyword>
  <keyword>Anaplastic Oligodendroglioma</keyword>
  <keyword>Diffuse Astrocytoma</keyword>
  <keyword>Oligodendroglioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Neuroepithelial</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
    <mesh_term>Choroid Plexus Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

